Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-083136
Filing Date
2025-06-06
Accepted
2025-06-06 16:31:09
Documents
2
Period of Report
2025-06-04

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1602
2 EX-24 cadl-ex24.htm EX-24 11711
  Complete submission text file 0000950170-25-083136.txt   14904
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Issuer) CIK: 0001841387 (see all company filings)

EIN.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O ALTO NEUROSCIENCE, INC. 650 CASTRO STREET, SUITE 450 MOUNTAIN VIEW CA 94041
Business Address
Radhakrishnan Maha (Reporting) CIK: 0002013423 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40629 | Film No.: 251031198